Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
X-ray photon trajectory during the simulation phantom study from the side and top views. Due to scattering of the X-rays when they hit the lower end of the patient bed, exposure in mainly to the lower body of the interventional echocardiographer performing transesophageal echocardiography. The green lines are the scattered photon trajectories calculated by Monte Carlo simulation in the study.

Radiation exposure in the cath lab: Tracking the impact on interventional echocardiographers

Researchers found that echocardiographers in the cath lab are exposed to high doses of radiation on the right half of their body, especially the waist and lower body. 

New ASE guideline outlines training standards for interventional echocardiography

The American Society of Echocardiography (ASE) released a new guideline document that outlines uniform training standards for interventional sonographers guiding structural heart procedures.

Raj Makkar, MD, Cedars-Sinai’s vice president of Cardiovascular Innovation and Intervention and the Stephen R. Corday, MD, Chair in Interventional Cardiology, explains the ACC 2023 results on the safety and efficacy of transcatheter edge-to-edge mitral valve repair in degenerative mitral regurgitation (MR) study. It was a review of data is from the STS/ACC TVT Registry that was presented at the American College of Cardiology (ACC) 2023 meeting.

New data on real-world TEER outcomes in patients with degenerative MR

TEER can significantly improve a patient's chances of survival, new findings confirm.

The Medtronic CoreValve Evolute on display at ACC 2022. The valve performed better than surgical valved in terms on structural deterioration. #ACC22

Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves

Researchers evaluated data from more than 200 patients who underwent redo TAVR, noting that women and patients with a higher BMI faced a higher risk of coronary flow compromise.

layoffs staff cuts termination workforce

Medtronic laying off undisclosed number of employees to reduce costs

“These decisions are never easy, and we’re taking great care to treat all impacted employees with dignity and respect," the company told Cardiovascular Business in a statement.

ACS and revascularization after TAVR: New data on a high-risk scenario

“It is vital to identify patients who are at a high risk for ACS after TAVR for potential treatment beforehand,” according a new analysis published in the American Journal of Cardiology.

The LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) device

Cardiologists make history, perform TTVR with new-look valve for first time in U.S.

The new valve was placed inside the damaged valve via a catheter that is inserted through a small incision in the patient's neck. 

Thumbnail

TAVR vs. SAVR in patients with pure aortic regurgitation: Key insights from a new Cleveland Clinic study

Patients with pure native AR are often excluded from clinical trials comparing TAVR and SAVR, leading to a lack of clarity when it comes to the proper treatment of this population.

Displaying 433 - 440 of 1006
Design by Adaptive Theme